Illumina microarray was used to identify differentially expressed genes in three epithelial ovarian cancer (EOC) cells. To validate the microarray data, mRNA and protein level of glucose transporter-1 (GLUT-1) was examined. GLUT-1 had an EOC/normal cells ratio of 5.51 based on microarray. Real-time PCR and immunohistochemistry demonstrated that GLUT-1 expression was significantly increased in EOC (p = .029 and p < .001, respectively). On survival analysis, GLUT-1 overexpression (HR = 4.80, p = .027) and lymph node metastases (HR = 8.35, p = .016) conferred a significantly worse overall survival. In conclusion, GLUT-1 expression is remarkably upregulated in EOC and predicts a poor overall survival.
Bibliographical noteFunding Information:
This work was supported in part by grants from the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2011-0005230, 2011-0010286, and 2011-0007146) and faculty research grants from Yonsei University College of Medicine for 2010 and 2011 (3-2010-0072 and 6-2011-0073).
Paraffin-embedded samples of ovarian cancers were collected between April 2008 and December 2010 and stored at the Gangnam Severance Hospital pathology department archives. Some of the paraffin blocks were provided by the Korea Gynecologic Cancer Bank through Bio & Medical Technology Development Program of the Ministry of Education, Science and Technology, Korea. Fresh-frozen tissues from a different group of ovarian cancer, and borderline ovarian tumor patients were obtained from women who underwent elective surgery at the Gangnam Severance Hospital between November 2008 and July 2010. Tumor specimens were harvested immediately after surgical procedures, snap-frozen in liquid nitrogen, and then stored at −80◦C until RNA extraction. None of the included patients had a prior diagnosis of cancer or had received chemotherapy or surgery for the present disease. All ovarian cancer patients were surgically staged according to the criteria of the FIGO staging system. All stage I/II ovarian cancer patients had pelvic and paraaor-tic lymph node (LN) dissection according to the National Comprehensive Cancer Network (NCCN) clinical practice guidelines. Study approval was obtained from the institutional review board (IRB) of Gangnam Severance Hospital, and all patients signed informed consent forms according to institutional guidelines before sample collection.
All Science Journal Classification (ASJC) codes
- Cancer Research